> ## Content Index
> Fetch the complete content index at: https://www.bullished.co/llms.txt
> Use this file to discover other available public pages before exploring further.

# Medicare's Proposed WiSE Coverage Would Require Studies Tracking Deaths For At Least 24 Months
- URL: https://www.bullished.co/medicares-proposed-wise-coverage-would-require-studies-tracking-deaths-for-at-least-24-69e8017a/
- Published: 2026-11-18T21:56:12.000Z
- Updated: 2026-11-18T21:56:12.000Z
- Description: The heart-pacing proposal targets patients conventional treatment cannot serve; public comments close December 18, 2026.
- Author: Matteo Parrino
- Tags: Markets, EBRCZ, Industry: Healthcare, Topic: Health & Drug Regulation

Medicare would pay for WiSE leadless heart-pacing treatment only through approved studies tracking deaths, or deaths and heart-failure hospitalizations, for at least [24 months](https://www.cms.gov/medicare-coverage-database/view/ncacal-decision-memo.aspx?proposed=Y&ncaid=322&ref=bullished.co). The Centers for Medicare & Medicaid Services (CMS) proposed the policy Wednesday for selected patients whose conventional treatment failed or whose standard device upgrade would be too risky.

## Payment tied to patient evidence

The proposal would establish a national coverage determination — a Medicare policy specifying when the program pays for a treatment — for leadless ultrasound-based cardiac resynchronization therapy. The treatment aims to coordinate contractions of the heart's ventricles.

CMS would use coverage with evidence development: Medicare would pay only when eligible patients enroll in a CMS-approved study. Related items and services would qualify within those studies, including inpatient hospital treatment, qualifying outpatient hospital care and physicians' services.

The proposed patient criteria restrict payment to people with heart failure who need cardiac resynchronization therapy. They must already have an implanted system that paces the right ventricle or be eligible to receive one. Use of the leadless system would also have to match the indication authorized by the Food and Drug Administration.

Patients would need to fall into a category defined by a problem with conventional treatment. One category includes people whose previous coronary-sinus pacing-wire implantation failed or whose implanted wire was switched off. The other covers people who already have a pacemaker or implantable cardioverter-defibrillator but face medical reasons that make a standard upgrade inadvisable.

Anatomical, physiological or other evidence-based risk factors could place patients in either category. The policy remains a proposal, and public comments close December 18, 2026.

## Studies must measure survival

CMS would require an active comparison group treated during the same period as the study patients. The studies' main outcome would be death from any cause, or a combined measure of deaths and heart-failure hospitalizations, followed for a [minimum 24 months](https://www.cms.gov/medicare-coverage-database/view/ncacal-decision-memo.aspx?proposed=Y&ncaid=322&ref=bullished.co). Studies using the combined measure would have to report each component separately.

The designs would also need to support analyses by clinically important demographic characteristics and by patients' burden of other illnesses. CMS specified groups living with two, three, four or more significant conditions. Its examples include chronic kidney disease, diabetes, hypertension, chronic obstructive pulmonary disease, high cholesterol and heart-rhythm disorders, including atrial fibrillation.

Study populations would need to represent the demographic and clinical diversity of Medicare patients intended to receive the treatment. Protocols would explain how eligibility rules affect enrollment of traditionally underrepresented groups and how investigators plan to retain those patients and report their outcomes.

Sponsors would need the staff, skills and resources to finish their studies, plus a written schedule covering enrollment, interim findings and final results. Before a study begins, investigators would register it on ClinicalTrials.gov and deliver a complete final protocol and statistical analysis plan to CMS. Changes to approved protocols would require public explanation.

CMS's standards would require attention to bias, data completeness, accuracy and whether observation lasts long enough to assess durable outcomes. Investigators would also test how robust their findings are under alternative statistical assumptions.

Final results would have to reach CMS and be submitted for publication or made publicly accessible within 12 months of the study's primary completion date. Sponsors would commit to sharing data, methods, analytical code and results with CMS or an approved third party, subject to privacy requirements.

## WiSE's route to Medicare

EBR Systems, which develops and sells the WiSE CRT System, is the company that [requested the coverage](https://www.cms.gov/medicare-coverage-database/view/ncacal-tracking-sheet.aspx?ncaid=322&ref=bullished.co). Its implantable device uses ultrasound energy to stimulate the left ventricle without a pacing wire.

WiSE is the company's only product. It works alongside an implanted pacemaker or defibrillator to help coordinate pumping; another cardiac device supplies the accompanying rhythm treatment. EBR sells the system to hospitals, focusing its commercial business on selected high-volume U.S. medical facilities.

The proposed patient groups match the system's intended use: people conventional pacing-wire treatment has failed to serve, or those considered at high risk for a standard upgrade. CMS's analysis focuses on which patient characteristics and other illnesses are associated with better outcomes, including survival and heart-failure hospitalizations.

EBR nominated WiSE for the Transitional Coverage for Emerging Technologies pathway on October 30, 2024\. CMS accepted the nomination on January 17, 2025, and accepted the formal coverage request on June 3, 2026.

CMS expects to complete its [coverage decision](https://www.cms.gov/medicare-coverage-database/view/ncacal-tracking-sheet.aspx?ncaid=322&ref=bullished.co) by February 16, 2027.

### Sources

- [Proposed decision memo — Leadless CRT - Wireless Stimulation Endocardially (WiSE)](https://www.cms.gov/medicare-coverage-database/view/ncacal-decision-memo.aspx?proposed=Y&ncaid=322&ref=bullished.co) — Centers for Medicare & Medicaid Services
- [National coverage analysis tracking sheet — Leadless CRT - Wireless Stimulation Endocardially (WiSE)](https://www.cms.gov/medicare-coverage-database/view/ncacal-tracking-sheet.aspx?ncaid=322&ref=bullished.co) — Centers for Medicare & Medicaid Services
- [What Happens When Healthcare Technology Starts With People](https://finance.yahoo.com/healthcare/articles/happens-healthcare-technology-starts-people-171000605.html?ref=bullished.co) — Yahoo Finance
- [CorVista Health Launches Clinical Decision Support and Commercial Availability of PCWP Algorithm, Taking the CorVista® Platform from Testing to Guideline-Driven Action](https://www.businesswire.com/news/home/20261118570037/en/CorVista-Health-Launches-Clinical-Decision-Support-and-Commercial-Availability-of-PCWP-Algorithm-Taking-the-CorVista-Platform-from-Testing-to-Guideline-Driven-Action?ref=bullished.co) — businesswire.com
- [November Journal of Cardiac Failure Focus Issue on Artificial Intelligence: AI Echo Raises HFpEF Detection to 78%](https://www.prnewswire.com/news-releases/november-journal-of-cardiac-failure-focus-issue-on-artificial-intelligence-ai-echo-raises-hfpef-detection-to-78-302942797.html?ref=bullished.co) — prnewswire.com